Journal
FRONTIERS IN NEUROLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2022.900582
Keywords
atrial fibrillation; ischemic stroke; embolic stroke; embolic stroke of undetermined source; ESUS
Categories
Funding
- Carlos III Institute of Health (RICORS-ICTUS) [RD21/0006/0010]
Ask authors/readers for more resources
This study developed a screening for atrial fibrillation scale (SAFE) to select ischemic stroke patients at higher risk of atrial fibrillation (AF) for a more thorough evaluation. The SAFE scale showed good sensitivity and specificity in identifying patients with paroxysmal AF.
Background and PurposeAn individual selection of ischemic stroke patients at higher risk of atrial fibrillation (AF) might increase the diagnostic yield of prolonged cardiac monitoring and render it cost-effective. MethodsThe clinical, laboratory, and brain/cardiac imaging characteristics of consecutive ischemic stroke patients without documented AF were recorded. All patients underwent at least 72 h of cardiac monitoring unless AF was diagnosed before, transthoracic echocardiogram, blood biomarkers, and intracranial vessels imaging. A predictive grading was developed by logistic regression analysis, the screening for atrial fibrillation scale (SAFE). ResultsA total of 460 stroke patients were analyzed to develop the SAFE scale, a 7-items score (possible total score 0-10): age >= 65 years (2 points); history of chronic obstructive pulmonary disease or obstructive sleep apnea (1 point); thyroid disease (1 point); NT-proBNP >= 250 pg/ml (2 points); left atrial enlargement (2 points); cortical topography of stroke, including hemispheric or cerebellar cortex (1 point); and intracranial large vessel occlusion (1 point). A score = 5 identified patients with paroxysmal AF with a sensitivity of 83% and a specificity of 80%. ConclusionScreening for atrial fibrillation scale (SAFE) is a novel and simple strategy for selecting ischemic stroke patients at higher risk of having AF who can benefit from a more thorough etiological evaluation. External validation of SAFE in a multicenter study, with a larger number of patients, is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available